tm
Seeing Is Believing
tm
Seeing Is Believing
NBSE is currently covered by 3 analysts
NeuBase Therapeutics's activity chart (see below) currently has 9 price targets and 12 ratings on display. The stock rating distribution of NBSE is 80% BUY and 20% HOLD.
Analysts average stock forecasts to be materialized ratio is 12.5% with an average time for these price targets to be met of 92.75 days.
Highest price target for NBSE is $23, Lowest price target is $6.
Most recent stock forecast was given by HARTAJ SINGH from OPPENHEIMER on 21-Oct-2022. First documented stock forecast 29-Oct-2019.
Currently out of the existing stock ratings of NBSE, 4 are a BUY (80%), 1 are a HOLD (20%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$280
3 years 11 months 1 days ago
(21-Oct-2022)
0/1 (0%)
$153.6 (121.52%)
Buy
3 years 11 months 5 days ago
(17-Oct-2022)
0/2 (0%)
$255.8 (245.49%)
Buy
$360
4 years 3 months 22 days ago
(31-May-2022)
0/2 (0%)
$126.2 (53.98%)
Buy
$15
$14 (1400.00%)
$320
5 years 1 months 6 days ago
(16-Aug-2021)
1/2 (50%)
$-54.8 (-78.51%)
371
What is NBSE (NeuBase Therapeutics) average time for price targets to be met?
Which analyst most recently updated their price target on NBSE (NeuBase Therapeutics)?
Which analyst has the current lower performing score on NBSE (NeuBase Therapeutics) with a proven track record?
Which analyst has the most public recommendations on NBSE (NeuBase Therapeutics)?
Which analyst is the currently most bullish on NBSE (NeuBase Therapeutics)?
Which analyst is the currently most reserved on NBSE (NeuBase Therapeutics)?
